Several clinical trials in humans confirmed the erythropoietic effect of HIF‐PH inhibitors in anemic patients with chronic kidney disease (CKD) by observation of increasing hemoglobin (Hb) concentrations comparable to those observed with administration of recombinant EPO.1, 3, 4, 5. The gene discussed is GSTM1; the disease is chronic kidney disease.